awmsg logo



midostaurin (Rydapt®)


Reference No. 3584

Publication date:
12/12/2017


Appraisal information

midostaurin (Rydapt®) 25 mg capsule


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 08/12/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, midostaurin (Rydapt®) cannot be endorsed for use within NHS Wales for use as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.
Statement of Advice (SOA)
Download